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Summary 
Many novel therapeutic options for depression exist which are either not mentioned in clinical 
guidelines or recommended only for use in highly specialist services.  The challenge faced by clinicians 
is when it might be appropriate to consider such ‘non-standard’ interventions.  This analysis proposes 
a framework to aid this decision. 
Introduction 
There are numerous effective psychological therapies and drug treatments for the management of 
major depressive disorder (MDD) and guidelines for their use (e.g. those from the UK’s National 
Institute for Health and Care Excellence (NICE)1 or British Association for Psychopharmacology (BAP)2).  
However, a major challenge is improving the management of MDD patients who do not experience 
full or sustained remission of symptoms with standard, guideline recommended, treatments or who 
cannot tolerate them.  A major issue is that many of the recommended treatments have similar 
mechanisms of action and in naturalistic studies there appears to be minimal difference in 
effectiveness between them.1,2  In addition, duration of depression is associated with worse 
outcomes,3 including social breakdown such as loss of job or relationship4 which in themselves can 
become barriers to recovery.  Fortunately, many alternative treatments, with potentially different 
mechanisms of action, exist which are either currently not included in guidelines or are only 
recommended for use in specialist services – we refer to these as ‘non-standard’.  These interventions 
are characterised by having a more limited evidence base to support their use, being associated with 
greater risks or invasiveness, and/or being more costly than standard treatments.  The important 
clinical question is when to consider them for a particular patient. 
Problems and possible solutions 
The answer to the question is in some ways simple.  If the probability of responding to (or tolerating) 
a further standard treatment is very low then a case can be made for using a non-standard treatment.  
However, the evidence based from which to draw such conclusions is far from ideal.  Studies vary in 
their definitions of degree of treatment resistance necessary for inclusion.  For example, the data 
supporting the use of quetiapine augmentation of antidepressants was obtained in studies of patients 
who had had a sub-optimal response to their first, or possibly second, antidepressant.5  Inclusion in 
some studies is defined as much by chronicity as lack of treatment response.6  What studies there are 
tend to relate to patients who are treatment non-responsive rather than partially responsive, or to 
patients who have strong preferences for some treatments but not others.7  Overall, it is also 
important to note, there is little robust evidence from prospective sequential RCTs for the efficacy of 
options beyond third or fourth sequential treatments.8 
One possible solution is to consider non-standard interventions only when all standard ones have been 
tried and failed.  However, adequate trials of all possible combinations of pharmacotherapy alone 
would take literally decades.  The evidence base does not support this strategy.  Naturalistic data 
suggests that the response rate of patients with chronic TRD to standard interventions is only around 
10% over one year.6  Further evidence suggests that the duration of untreated depression has a 
negative impact on eventual response.3  It is therefore clinically questionable to cycle endlessly 
through pharmacologically similar strategies.9 
An alternative option is to use a ‘threshold’ approach.  Conway and colleagues proposed ‘treatment 
resistant depression’ (TRD) be divided into “stage I” defined as failure of two interventions 
(medication or psychotherapy) and “stage II” defined as failure of three interventions.9  They propose 
that less invasive non-standard interventions could be considered for “stage I TRD” and more invasive 
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interventions (e.g. vagal nerve stimulation (VNS) or deep brain stimulation (DBS)) for “stage II TRD”.9  
This threshold would allow for DBS for a patient after failure of 20 mg of fluoxetine and 20mg of 
citalopram, both prescribed over 6 weeks, and 8 sessions of cognitive behaviour therapy (CBT).  We 
believe this is premature.  This also illustrates the problem of a simple threshold approach with the 
challenge being how to find the best balance between timely access to alternative treatments versus 
unnecessary exposure to risky/expensive interventions.  The threshold for different interventions is 
also likely to be different with, for example, the threshold for ablative neurosurgery being substantially 
higher than for a well-tolerated and safe non-standard medication.  There are also a myriad of patient 
and illness factors that will also influence when a particular treatment might be deemed appropriate. 
Rather than a simple threshold we suggest a more nuanced approach with a defined reference point, 
which we refer to as ‘multi-therapy resistant MDD’ (MTR-MDD), to help guide clinicians, patients and 
commissioners. 
‘Multi-therapy resistant-MDD (MTR-MDD)’ 
The criteria proposed for MTR-MDD (outlined in Table 1), for the reasons outlined above, are based 
more on consensus than clear cut evidence.  They have been developed by clinicians drawn from 
primary care, secondary care and specialist services (see the authors’ disclosure statements), including 
individuals with personal experience of MDD. 
The intention is that the MTR-MDD criteria can be broken down into its various component parts to 
help guide discussions between clinicians, patients, and commissioners about when it may be 
reasonable to consider non-standard intervention.  In totality the criteria provide something of a ‘back 
stop’ – if a patient meets all of the criteria but has not been considered for non-standard treatment, 
then the question “why not?” should be asked.  We do not posit that MTR-MDD defines a specific sub-
group of patients with MDD that may be characterised, for example, by a specific biology.  However, 
the categorisation is potentially of use in research for stratification in trials of patients with particularly 
difficult to treat illness. 
The term ‘multiple-therapy-resistant-MDD’ has been chosen to reflect that: several interventions 
(more than two) must have failed to produce or maintain a response, or have been intolerable;  non-
pharmacological interventions should also have been tried and been ineffective or intolerable; and 
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Table 1:  Proposed criteria for MTR-MDD 
The Patient:  Diagnosed with MDD (using the Diagnostic and Statistical Manual, 5th edition (DSM-
5)) 
Their depression:  MDD of at least moderate severity. 
Their treatment: 
 Psychotherapy.  At least two trials of structured, evidence-supported psychological 
therapy.1  The trials should ideally each be of a different modality and provided by a 
different therapist.  In both cases, the clinician should assure themselves that the patient 
has received a structured course of therapy delivered by an experienced therapist with 
whom the patient had a good therapeutic relationship.  Ideally, at least one of the trials 
should have been of at least 16 hours duration and at least one trial should have been given 
in combination with pharmacotherapy. 
 Antidepressants.  Four adequate trials of antidepressants.  There is little consensus with 
regards how antidepressants should be divided into different ‘classes’ and how important 
it is that drugs from different classes are trialed.  However, it is recommended that the trials 
should not all be from the same class of drugs and that at least two trials are using 
antidepressants that are viewed as being potentially more efficacious in severe depression 
and/or compared to other antidepressants, for example as listed by BAP guidelines 
(clomipramine, venlafaxine (⩾150 mg), escitalopram (20 mg), sertraline, amitriptyline or 
mirtazapine).2  We would also recommend consideration of a traditional MAOI (e.g. 
phenelzine), especially for patients with atypical symptoms. 
 Pharmacological augmentation.  At least two adequate trials of an evidence based 
augmentation/combination agent given in combination with an antidepressant.  Ideally 
these should both be agents listed as first line options in BAP Guidelines (lithium (ideally 
with a plasma level of 0.6 – 1.0 mmol/l), quetiapine and aripiprazole).2 
 ECT.  A trial of ECT (at least 8 treatments, and ideally bilateral if tolerated).  
For all treatments:  The requirement for a treatment may be waived if there is a recognised 
contraindication or the patient has, despite extensive discussions and the provision of information, 
declined it, or there have been well-documented adverse effects that have limited tolerability.  This 
applies to ECT, psychotherapy and medication. 
 
Given evidence for possible greater efficacy of a structured psychological treatment in combination 
with medication10,11, a period of combined treatment, possibly over a period of 9-15 months, is 
recommended.   
 
 
The full MTR-MDD criteria are met if there has been a failure to respond, achieve remission, maintain 
a response/remission or tolerate all the treatments listed in table 1.  For many patients, it can be 
difficult distinguishing discrete episodes.  It is inappropriate to re-trial medications that have failed in 
previous episodes unless the patient describes previous non-adherence and willingness to retry.  As a 
result, these failures will usually be defined over the life-time of the patient. 
As in any area of medicine, non-response to an intervention should lead to a re-appraisal of the 
diagnosis.12  Alternative primary diagnoses such as bipolar disorder should be carefully excluded.  
Comorbidities that may be contributing to the resistant nature of the MDD, such as substance use 
disorders, personality disorders, anxiety disorder and attention deficit and hyperactivity disorder 
(ADHD), should be identified and treated vigorously.  Similarly, psychosocial maintain factors should 
be addressed where possible.  However, the presence of such comorbidity does not negate a patient 
meeting criteria and hence consideration being given to non-standard interventions. 
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For all medications, an adequate trial is one where the clinician is confident (based on clinical 
judgement and patient history) that the patient has been adherent to a maximum licensed, or 
maximum-tolerated, dose for an adequate period of time.  In the case of a maximum tolerated dose, 
this must be a dose equivalent or higher than the generally regarded minimal therapeutic dose (e.g. 
as defined in the drug license).  If a patient is not able to tolerate a minimum therapeutic dose, then 
the trial would be deemed to have failed on the basis of intolerance. 
First and second line treatment trial durations are recommended to be 4-6 weeks, but for patients 
with resistant depression longer trials are recommended.1,2  We recommend that at least one, and 
ideally two trials of antidepressants have been used for a minimum duration of eight weeks at 
maximum or maximum tolerated doses based on the need to balance ‘efficiency’ of a trial (shortest 
reasonable time) with the need to confidently exclude a potential response.  The duration of 
augmentation trials is rarely described in guidelines.  RCT data suggests a relatively rapid response to 
some agents, for example antipsychotic augmentation (e.g. quetiapine5), while other strategies may 
take longer at least in part due to the time needed to reach a therapeutic level (e.g. lithium).  
Nevertheless, we would recommend a minimum of a four weeks, and ideally eight weeks, at a 
therapeutic dose, for augmentation trials. 
With regards to non-tolerance, in almost all circumstances, clinicians should endeavour to establish 
that all reasonable efforts have been taken to ensure that the patient can tolerate at least the 
minimum therapeutic dose.  This may require extended dose titration periods, using preparations that 
allow starting at very low doses, the use of other medications (such as benzodiazepines for example 
when using an activating drug such as aripiprazole) and frequent review.  In many situations, the 
clinician should recommend at least one other drug from the same drug class to ensure that 
intolerance is class rather than drug-specific.   
Determining the adequacy of a course of psychotherapy may be more difficult, as factors not always 
directly-related to the patient or their illness have been demonstrated to impact on outcome, 
including therapeutic alliance, therapist adherence to the therapeutic modality and match between 
patient and therapeutic modality.13-15  Some patients need several months of preparation by clinicians 
or psychotherapists to develop the psychological mindedness to benefit from a course of any 
psychotherapy.  These considerations and assessment of past psychotherapy may of itself be a 
justification for seeking an expert psychotherapy opinion. 
The rationale for including ECT as a requirement in the MTR-MDD criteria is that ECT is, for most 
people, a choice that offers a high chance of improvement16 and acceptable levels of risk compared 
with more advanced and/or less evidence based options.  However, a failure of ECT to lead to a 
maintained response despite antidepressant prophylaxis, or a refusal/inability to undergo a trial of 
ECT, would be an appropriate prompt to consider alternative interventions with patients, especially if 
they meet MTR-MDD criteria. 
Using the MTR-MDD Criteria to guide the use of non-standard treatments 
Non-standard interventions can be considered to exist on a spectrum.  At one end, there are those 
which have a relatively strong evidence base to support their use in MDD, are easy to implement, well 
tolerated, non-invasive and relatively cheap.  At the other end, interventions have more limited 
evidence to support them, their use is more complex to undertake, they are associated with more 
risks or invasiveness, and/or they are of higher costs than standard interventions.  The position of an 
intervention on the spectrum also depends on its regional and national availability and the expertise 
of the clinician(s) using it.  Infrequently used interventions are more likely to be appropriate for 
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specialised centres.  This, as well as other factors, is prone to change over time as more evidence is 
acquired.   
Consideration of these issues can help decisions about the potential position in the treatment 
algorithm of specific non-standard interventions.  Interventions supported by RCT data, well tolerated 
and of a similar cost to standard treatments are likely to be used early on.  It may well be totally 
inappropriate to wait till a patient has a duration of illness of two years and/or has had three episodes 
of illness.  When such interventions are used will be determined primarily by clinician expertise and 
local availability. 
The threshold for some non-standard interventions may be determined by individual elements of the 
MTR-MDD criteria.  For example, transdermal selegiline has been shown to be particularly effective in 
patients with atypical depression,17 but in many parts of the world is extremely expensive to acquire.  
As a result, it is probably reasonable that the MTR-MDD antidepressant criteria are met, including that 
a standard monoamine oxidase inhibitor (MAOI) that irreversibly blocks MAO-B is tried first.  Similarly, 
the complex psychotherapy Cognitive Behavioural Analysis System of Psychotherapy (CBASP) which 
has data supporting its use in treatment resistant MDD18 but which is non-standard primarily because 
of limited availability, is likely to only be considered if a patient meets the MTR-MDD psychotherapy 
criteria. 
Modafinil is not included in NICE depression guidelines,1 though it is mentioned as an option for use 
in specialist centres in BAP guidelines2 on the basis of four RCTs conducted in primarily non-treatment 
resistant MDD patients.19  In general it is well tolerated and can be combined with most 
antidepressants.  It is therefore at the more benign end of the non-standard therapy spectra.  It would 
seem reasonable to consider this if the MTR-MDD criteria for pharmacological augmentation are met.  
Conversely, pramipexole, which is supported by just two conflicting RCTs20 and is more complex to use 
(due to the potential for impulse control disorders such as gambling)21 is likely to be considered only 
after a range of interventions have been unsuccessful i.e. beyond MTR-MDD augmentation criteria.  
Further along the spectra, Intravenous ketamine, which is supported by a number of studies but which 
is also associated with risk, invasiveness and limited duration of effect22 is likely to only be used if 
broader MTR-MDD criteria are met. 
There are an increasing number of non-drug physical treatments for MDD that vary in their degree of 
invasiveness.  Transcranial magnetic stimulation (TMS) is well tolerated and supported by NICE 
recommendations.23  Hence by our definitions it is a ‘standard’ intervention though its use is limited 
by availability.  It may be considered before ECT in the treatment algorithm for some patients at less 
immediate risk.  Conversely, VNS has been reviewed by NICE and recommended for use only “with 
special arrangements for clinical governance, consent and audit or research”.24  It might be 
appropriate to consider this if ECT has been considered inappropriate, unacceptable or it has led to 
an inadequate response.  Given its cost and limited availability it is also likely that patients will meet 
the other criteria MTR-MDD criteria.  The full MTR-MDD criteria are likely to be the bare minimum for 
consideration of anterior cingulotomy or other neurosurgical procedure, though the concern is that 
even for this highly invasive irreversible intervention there is often currently too long a delay before a 
patient is considered for this. 
Clearly an additional factor that influences where an intervention is placed in the algorithm is the 
patient.  For example, a concern about medication may lead to the use of a non-invasive relatively 
cheap non-drug physical intervention such as TMS early on.  Alternatively the clinical characteristics 
of a patient may influence choice.  With regards to standard interventions an example would be the 
use of ECT early on for patients with psychotic depression or marked psychomotor retardation.  
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Similarly, VNS might be considered for patients with highly recurrent depression despite ongoing 
prophylactic medication.25  
Discussion 
With the welcome burgeoning of novel non-standard interventions, the question is where in the 
treatment algorithm they should be used.  The appropriate place will vary between patients and 
interventions.  Clinical decisions regarding this are a complex interplay between various factors such 
as: the patient’s clinical state; research evidence; patient preference and expectations; and the 
expertise and experience of the clinician.  A significant concern is that non-standard interventions are 
only brought into consideration much later than might be appropriate and that this is to the detriment 
of the patient, though they may also be used inappropriately early in some situations.  We argue that 
the framework and MTR-MDD criteria described in this paper should complement clinical expertise 
rather than replace it, to act as a reference point around which to gauge when it is clinically 
appropriate to use non-standard interventions.  We believe that a patient meeting all of the MTR-
MDD criteria should be considered for non-standard treatment if this has not already happened.  The 
criteria also act as a prompt for clinicians with regards standard interventions.  Whether MTR-MDD 
criteria are appropriate for all age groups, including adolescents, is an open question.  At the very least 
we hope that this analysis piece prompts debate around these issues. 
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